SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lasa Supergenerics gains on getting WHO Certificate of Good Manufacturing Practices for Khed unit

13 Jan 2021 Evaluate

Lasa Supergenerics is currently trading at Rs. 95.30, up by 0.60 points or 0.63% from its previous closing of Rs. 94.70 on the BSE.

The scrip opened at Rs. 96.40 and has touched a high and low of Rs. 97.35 and Rs. 95.05 respectively. So far 14238 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 100.15 on 08-Jan-2021 and a 52 week low of Rs. 22.25 on 20-Jan-2020.

Last one week high and low of the scrip stood at Rs. 100.15 and Rs. 85.10 respectively. The current market cap of the company is Rs. 387.41 crore.

The promoters holding in the company stood at 64.47%, while Non-Institutions held 35.53% stake in the company.

Lasa Supergenerics has received WHO Certificate of Good Manufacturing Practices from the Food and Drug Administration authorities for its manufacturing facility situated at Khed (Ratnagiri).

WHO GMP covers all aspects of production starting from the materials, premises and equipment to the training and personal hygiene of staff. Detailed, written procedures which are essential for each process that could affect the quality of the finished product. Systems to provide documented proof that correct procedures are consistently followed at each step in the manufacturing process - every time a product is made.

Lasa Supergenerics is pioneer and amongst the leading players in the manufacturing of APIs in India through its catalyst chemistry expertise and fully backward integrated unit.

Lasa Supergenerics Share Price

8.47 0.33 (4.05%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×